Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up with rival Novo Nordisk A/S. Starting Monday, the lowest dose vial will cost ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

Drugmaker Eli Lilly is rolling out a new model to make it easier for employers to provide access to its GLP-1 drugs for weight management. Lilly said in an announcement that the model is built on ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) released data from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in ...

Lilly's drug shows weight reduction from 9.5% to up to 20.1% Plans to start late-stage trials by year end Eloralintide mimics the pancreatic hormone amylin Nov 6 (Reuters) - Eli Lilly (LLY.N), opens ...

Eli Lilly (LLY) said on Thursday that eloralintide, its experimental amylin receptor agonist for obesity, helped patients lose up to 20% of their weight in a mid-stage trial involving obese or ...

Eli Lilly has linked its amylin agonist eloralintide to up to 20.1% weight loss at Week 48, encouraging the drugmaker to prepare to enter phase 3 next month. Lilly showed it is a contender for the ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...